Latest Antiretroviral drug Stories

A press release from PLoS ONEA new study by investigators from the University of North Carolina at Chapel Hill School of Medicine has confirmed the existence of a "trial effect" in clinical trials for treatment of HIV.Trial effect is an umbrella term for the benefit experienced by study participants simply by virtue of their participating in the trial. It includes the benefit of newer and more effective treatments, the way those treatments are delivered, increased care and...

In a result that will fundamentally change approaches to HIV prevention in Africa, an international study has demonstrated that individuals at high risk for HIV infection who took a daily tablet containing an HIV medication "“ either the antiretroviral medication tenofovir or tenofovir in combination with emtricitabine "“ experienced significantly fewer HIV infections than those who received a placebo pill. These findings are clear evidence that this new HIV prevention strategy, called...

NEW YORK, July 13, 2011 /PRNewswire-USNewswire/ -- Results from two African studies of pre-exposure prophylaxis, or PrEP, released today provide clear evidence that the antiretroviral drugs used to treat HIV can also be used to prevent HIV among heterosexual men and women at risk of HIV infection. "These results are tremendously exciting and confirm that we are at pivotal period in the AIDS epidemic," said Mitchell Warren, AVAC executive director. "Antiretroviral (ARV) drugs for HIV...

PITTSBURGH and HYDERABAD, India, July 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan's Matrix Laboratories Limited. Matrix has licensed the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, if and when they receive regulatory approval. The Gilead products, which are currently in late-stage clinical development, include: Elvitegravir, an investigational integrase...

Johns Hopkins and South African scientists have further compelling evidence that new, simpler and shorter treatments with antibiotic drugs could dramatically help prevent tens of millions of people worldwide already infected with the bacterium responsible for tuberculosis, and especially those co-infected with HIV, from developing full-blown TB. That population includes as many as 22 million in sub-Saharan Africa who are already HIV positive and at high risk of also picking up TB, which is...

(Ivanhoe Newswire) -- New research may help explain why some patients with HIV experience neurological problems. Investigators have found that HIV weakens the blood-brain barrier -- a network of blood vessels that keeps potentially harmful chemicals and toxins out of the brain.Standard antiretroviral treatments suppress the replication of HIV and slow its progression. However, recent studies reveal that 40 to 60 percent of patients on these therapies continue to experience mild to moderate...

Although our body's defense mechanisms are usually capable of detecting and destroying many types of pathogens, some viruses are able to evade the immune system and make us sick. In particular, "retroviruses," such as human immunodeficiency virus (HIV), are notorious for eluding host immune defenses and causing disease. Now, a new study published by Cell Press online on June 30th in the journal Immunity identifies a key virus-sensing mechanism that is necessary for a successful...

ATLANTA, June 23, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine. The Los Angeles-based AIDS Research Alliance (ARA) will join with two existing members of GeoVax's clinical trial site team: the AIDS Research Consortium of Atlanta and the Alabama Vaccine Research Clinic at the University...

This observational cohort study, by Andrew Edmonds and colleagues, reports that treatment with highly active antiretroviral therapy (HAART) markedly improves the survival of HIV-infected children in Kinshasa, DRC, a resource-deprived setting. The findings presented suggest that HAART is as effective for improving the survival of HIV-infected children in a severely resource-deprived country (still recovering from civil war) as in more resource-privileged settings. Most observational studies on...

ROCKVILLE, Md., June 6, 2011 /PRNewswire-USNewswire/ -- The Guide for HIV/AIDS Clinical Care, a comprehensive roadmap for physicians, nurse-practitioners, dentists and other clinicians on how best to manage the long-term care of patients with HIV/AIDS, is now available online. Produced by the Health Resources and Services Administration (HRSA), the updated volume covers more than 90 topics and provides guidance on a broad range of clinical care issues, including testing and assessment,...